期刊文献+

重组人血小板生成素联合大剂量地塞米松对原发性ITP病人Treg细胞及Th1、Th2细胞的影响 被引量:4

Effect of the recombinant human thrombopoietin combined with high dose dexamethasone on the Treg cells,Th1 cells and Th2 cells in primary immune thrombocytopenia patients
下载PDF
导出
摘要 目的:观察重组人血小板生成素(rhTPO)联合大剂量地塞米松方案对原发性免疫性血小板减少症(ITP)病人调节性T细胞(Treg)及辅助性T细胞(Th)1、Th2表达水平的影响。方法:选择ITP病人82例,按照随机数字表法分为对照组40例和观察组42例。对照组给予大剂量地塞米松治疗,观察组在对照组治疗基础上加用rhTPO治疗。比较2组病人疗效,并采用流式细胞仪检测2组治疗前后Treg细胞和Th1、Th2细胞表达水平及Th1/Th2比例。结果:观察组病人疗效优于对照组(P<0.05)。治疗前,2组病人Treg细胞和Th1、Th2细胞表达水平及Th1/Th2比例差异均无统计学意义(P>0.05);治疗后,2组病人Treg细胞及Th2细胞均较治疗前明显上调(P<0.01),Th1细胞和Th1/Th2比例均较治疗前明显下降(P<0.01),且观察组Treg细胞及Th2细胞表达水平均明显高于对照组(P<0.01),Th1细胞和Th1/Th2均明显低于对照组(P<0.01)。结论:rhTPO联合大剂量地塞米松治疗原发性ITP能通过增加病人Treg细胞数量、纠正Th1/Th2细胞平衡,提高临床疗效。 Objective:To observe the effects of recombinant human thrombopoietin(rhTPO)combined with high dose dexamethasone on the expression levels of CD4+CD25+Foxp3+regulatory T cells(Treg),T-helper 1(Th1)cells and T-helper 2(Th2)cells in primary immune thrombocytopenia(ITP)patients.Methods:Eighty-two patients with ITP were divided into the control group(40 cases)and observation group(42 cases)according to the random number table method.The control group was treated with high-dose dexamethasone,and the observation group was treated with rhTPO on the basis of the control group.The therapeutic effects were compared between two groups.The expression levels of Treg cells,Th1 cells and Th2 cells,and the ratio of Th1/Th2 in two groups before and after treatment were detected using flow cytometry.Results:The total effective rate in observation group was significantly better than that in control group(P<0.05).Before treatment,there was no statistical significance in the expression levels of Treg cells,Th1 cells and Th2 cells,and the ratio of Th1/Th2 between two groups(P>0.05).After treatment,the levels of Treg cells and Th2 cells were significantly up-regulated(P<0.01),and the ratio of Th1 cells and Th1/Th2 decreased significantly compared with before treatment(P<0.01).After treatment,the expression levels of Treg cells and Th2 cells in observation group were significantly higher than those in control group(P<0.01),and the Th1 cells and Th1/Th2 ratio in observation group were significantly lower than those in control group(P<0.01).Conclusions:The rhTPO combined with high dose dexamethasone in the treatment of ITP can improve the clinical therapeutic effects through increasing the number of Treg cells and correcting the balance of Th1/Th2 cells.
作者 傅磊 沈磊 卞建军 李亮 苏玉璇 左金曼 孟美丽 陆尧 葛书亚 张伊莉 FU Lei;SHEN Lei;BIAN Jian-jun;LI Liang;SU Yu-xuan;ZUO Jin-man;MENG Mei-li;LU Yao;GE Shu-ya;ZHANG Yi-li(Department of Hematology,The Second Affiliated Hospital of Bengbu Medical College,Bengbu Anhui 233040,China)
出处 《蚌埠医学院学报》 CAS 2021年第7期858-862,共5页 Journal of Bengbu Medical College
基金 蚌埠医学院自然科学研究项目(BYKY2019156ZD)。
关键词 原发性免疫性血小板减少症 重组人血小板生成素 地塞米松 调节性T细胞 辅助性T细胞 primary immune thrombocytopenia recombinant human thrombopoietin dexamethasone regulatory T cells T-helper cells
  • 相关文献

参考文献10

二级参考文献73

  • 1赵永强,王庆余,翟明,徐健,陈协群,刘文励,张梅,宋善俊,王健民,孟凡义,单渊东.重组人血小板生成素治疗慢性难治性特发性血小板减少性紫癜的多中心临床试验[J].中华内科杂志,2004,43(8):608-610. 被引量:102
  • 2杨小猛,刘仿,陈群,赵丹,伍昌林,蔡康荣,肖红.特发性血小板减少性紫癜患儿Th1/Th2、Tc1/Tc2亚群漂移的研究[J].中国免疫学杂志,2005,21(1):76-79. 被引量:10
  • 3丁雪芹,周康兴,孙凌云.系统性红斑狼疮T细胞活化及其与病情活动的相关性研究[J].中华风湿病学杂志,2006,10(6):327-330. 被引量:5
  • 4BAO W, BUSSEL JB, HECK S, et al. Improved regulatory T- cell activity in patients with chronic immune thrombocytope- nia treated with thrombopoietic agents[ J ]. Blood ,2010,116 ( 22 ) :4639-4645.
  • 5张之南、沈悌,血液病诊断和疗效标准第三版[M],北京:科学出版社,2008:172-176.
  • 6FUJITA S, NAKANISHI T, OSHIMURA H, et al. TGF[3 (1) and sCTLA-4 levels are increased in ehrombopag-ex- posed patients with ITP[J]. Thromb Res,2012,130, (9) : 415-419.
  • 7KUBO M, MOTOMURA Y. Transcriptional regulation of the anti-inflammatory cytokine IL-10 in acquired immune cells. [ J] Front Immuno1,2012,3 ( 275 ) : 1-9.
  • 8OAKS MK, HALLETr KM. A soluble form of CTLA-4 in pa- tients with autoimmune thyroid disease [ J ]. lmmunol,2000, 164:5015-5018.
  • 9WAN YY, FLAWELL RA. ' Yin-Yang' functions of transfor- ming growth factor-beta and regulatory cells in immune reg- ulation. [ J] Immunol Rev,2007,220 : 199-213.
  • 10FOURNIE, G. J, CAUTAIN B, XYSTRAKIS E, et al. Cellular and genetic factors involved in the difference between Brown Norway and Lewis rats to develop respectively type-2 and type- 1 immune-mediated diseases[ J]. Immunol Rev,2001, 184 : 145-160.

共引文献485

同被引文献46

引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部